跳到正文

公司

Ono Pharma

Ono Pharma 的结构

Ono Pharma

公司

2 个关联
上游供应与依赖
同行竞争与合作
关系出现时间2026
Ono Pharma公司 · 2 个关联
第 1 层

上游供应与依赖1

同行竞争与合作1

关系

箭头表示关系方向,可按业务类别筛选。

  • 事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-10-08 16:00
      Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states
      查看来源
  • Biohaven签署协议 →Ono Pharma
    事实90%
    查看证据
    • 公司披露PR Newswire news releases2026-10-08 16:00
      Under the terms of the agreement, Ono will obtain an exclusive license to develop and commercialize BHV-1300, BHV-1310, and BHV-1320
      查看来源

显示第 1 至 2 条,共 2 条

结论

结合来源阅读结论,展开条目查看证据。

事实证据 1
签署协议Biohaven

Under the terms of the agreement, Ono will obtain an exclusive license to develop and commercialize BHV-1300, BHV-1310, and BHV-1320

PR Newswire news releases · 2026-10-08 16:00

查看证据
  • 公司披露PR Newswire news releases2026-10-08 16:00
    Under the terms of the agreement, Ono will obtain an exclusive license to develop and commercialize BHV-1300, BHV-1310, and BHV-1320
    查看来源
事实证据 1

Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states

PR Newswire news releases · 2026-10-08 16:00

查看证据
  • 公司披露PR Newswire news releases2026-10-08 16:00
    Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states
    查看来源

显示第 1 至 2 条,共 2 条

市场与估值

估值数据需要 Pro 或 Research。

升级到 Pro 解锁

暂无: 公司信号 · 财务数据 · 披露文件 · 业绩指引